Genomics Core
基因组学核心
基本信息
- 批准号:10269641
- 负责人:
- 金额:$ 22.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-16 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:BioinformaticsCDK4 geneCDK9 Protein KinaseCellsCessation of lifeChIP-seqChromatinClinicalClinical ResearchClinical TrialsCollectionComplexCyclin-Dependent KinasesDNA MethylationDNA Methyltransferase InhibitorDNA Modification MethylasesDNA Sequence AlterationDNA methyltransferase inhibitionDataData AnalysesDimensionsEZH2 geneEndogenous RetrovirusesEpigenetic ProcessEquipmentGene ExpressionGene MutationGenetic TranscriptionGenomicsGoalsHuman ResourcesImmuneImmune checkpoint inhibitorImmunizationImmunotherapyInflammasomeInterventionMethylationMutation DetectionPathologyPolycombPopulationPre-Clinical ModelPrincipal InvestigatorQuality ControlRepetitive SequenceResearch Project GrantsResourcesSamplingSignal TransductionSolid NeoplasmStatistical Data InterpretationT-LymphocyteTherapeuticTissuesTranslational ResearchTumor TissueTumor-infiltrating immune cellsbiobankcancer cellcancer therapydata acquisitiondata managementdata sharingdesignepigenetic therapyepigenomicsexhaustionexome sequencingexperimental studygenome-widehigh dimensionalityhigh throughput analysisinhibitor/antagonistinnovationmachine learning algorithmnovel therapeutic interventionpreclinical studypredicting responseprospectivesingle-cell RNA sequencingsynergismtargeted treatmenttranscriptome sequencingtranscriptomicstranslational studytumor
项目摘要
Abstract - Genomics, Epigenomics and Bioinformatics Core
The Genomics, Epigenomics, and Bioinformatics Core will provide personnel, equipment, and expertise to
support all projects of the Epigenetic Therapy SPORE. The Core will be a resource for design and execution of
genomic and epigenomic experiments, data acquisition, quality control, bioinformatic analysis, data
management, sharing and distribution. It will closely cooperate with all SPORE Projects and the
Pathology/Biospecimen Core. Project 1 studies immune-sensitization by inhibition of cyclin-dependent kinase
CDK9. It will discover whether clinically targetable CDKs are also epigenetic regulators and conduct pre-clinical
and clinical studies of combined epigenetic therapy and immunotherapy using CDK inhibitors, DNA
methyltransferase (DNMT) inhibitors and immune checkpoint inhibitors. The Core will analyze (i) gene
expression and chromatin accessibility in tumor and immune cells in preclinical models of tumors treated with
CDK9 inhibitors, (ii) genome-wide effects of CDK4, 6 and 7 inhibition on DNA methylation and gene
expression, and (iii) support preclinical studies and a clinical trial combining CDK9, DNMT and immune
checkpoints inhibitors by the analysis of collected samples for transcriptomic and epigenetic parameters (gene
expression and expression of endogenous retroviruses and repetitive elements by RNA-seq, DNA methylation
by RRBS) and immune cell parameters (gene expression and markers of exhaustion in sorted T cells). The
Core will also perform whole exome sequencing (WES) to determine whether baseline DNA mutation and DNA
methylation profiles predict response. Project 2 is focused on epigenetic synergy between inhibitors of DNMT
and Polycomb repressive complex subunits EZH1/2 for therapy in solid tumors. The Core will analyze and
integrate DNA methylation, ChIP-seq, RNA-seq and WES data to assess the combinatory effects of DNMT and
EZH1/2 inhibitors and perform single-cell RNA-seq analysis of the tumor tissue to delineate tumor-associated
immune populations. Project 3 combines induction of inflammasome signaling by hypomethylating agents with
inhibitors of polyADP-ribosylation to induce death of cancer cells. The Core will assess genome-wide and
LINE-1 repeat methylation. RNA-seq data will be analyzed for expression of ERVs and other repetitive
elements in tumors and sorted immune cells.
摘要-基因组学,表观基因组学和生物信息学核心
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jaroslav Jelinek其他文献
Jaroslav Jelinek的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jaroslav Jelinek', 18)}}的其他基金
相似海外基金
SCREENING FOR ABNORMALITIES IN CDK4 GENE IN PATIENTS W/ TYPE 1 & TYPE
筛查 1 型患者的 CDK4 基因异常
- 批准号:
6264831 - 财政年份:1998
- 资助金额:
$ 22.37万 - 项目类别:














{{item.name}}会员




